Stock RYTM RHYTHM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
39.14 USD +1.66% Intraday chart for Rhythm Pharmaceuticals, Inc. -10.56% -14.86%
May. 08 BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49 MT
May. 07 Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49
MT
Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell
MT
Rhythm Pharmaceuticals : RYTM 1Q2024 vFinal
PU
Transcript : Rhythm Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (RYTM) RHYTHM PHARMACEUTICALS Reports Q1 Revenue $26M, vs. Street Est of $26.9M
MT
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
GL
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
GL
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
AQ
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
CI
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
GL
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology
CI
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
GL
Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating
MT
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GL
Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock
MT
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
GL
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, C2 Life Sciences, Llc, Perceptive Discovery ID LP
CI
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RYTM Stock
  4. News Rhythm Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW